Background The global burden of disease attributable to respiratory syncytial virus (RSV)
remains unknown. We aimed to estimate the global incidence of and mortality from episodes …

Background We have previously estimated that respiratory syncytial virus (RSV) was
associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) …

Background The global burden of disease attributable to seasonal influenza virus in children
is unknown. We aimed to estimate the global incidence of and mortality from lower …

Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control …

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B. 1.1.
529 was announced, containing far more mutations in Spike (S) than previously reported …

Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

Summary Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for
emergency use by the UK regulatory authority, Medicines and Healthcare products …

Background Whether vaccination during pregnancy could reduce the burden of respiratory
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is …

Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV …

Background In countries with a high seroprevalence of human immunodeficiency virus type
1 (HIV-1), HIV infection contributes significantly to infant mortality. We investigated …